| Description | Ethoxzolamide (L-643786) is a carbonic anhydrase inhibitor. |
| In vitro | Ethoxzolamide（ETZ）处理在感染的巨噬细胞中引起了超过90%的报告基因GFP荧光抑制。此外，在为期9天的巨噬细胞存活试验中，Ethoxzolamide（ETZ）显著抑制了M. tuberculosis在细胞内生长的能力。 |
| Target activity | CA:1nM(Ki） |
| Synonyms | 依索唑胺, PNU-4191, Redupresin, L-643786 |
| molecular weight | 258.32 |
| Molecular formula | C9H10N2O3S2 |
| CAS | 452-35-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 150 mg/mL (580.68 mM), Sonication and heating are recommended. |
| References | 1. Benjamin K. Johnson, et al. The Carbonic Anhydrase Inhibitor Ethoxzolamide Inhibits theMycobacterium tuberculosis PhoPR Regulon and Esx-1 Secretion and Attenuates Virulence. Antimicrob Agents Chemother. 2015 Aug; 59(8): 4436–4445. 2. Song Gao, et al. Development and validation of an UPLC-MS/MS method for the quantification of ethoxzolamide in plasma and bioequivalent buffers: Applications to absorption, brain distribution, and pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Apr 1; 0: 54–59. 3. Maren TH, et al. Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide. Exp Eye Res. 1992 Jul;55(1):73-9. |